Fig. 2

Kaplan-Meier survival analysis comparing patients with KRAS amplified gastric adenocarcinomas (red lines) and patients without KRAS amplified gastric adenocarcinomas (blue lines). a Whole patient cohort including neoadjuvant and primary-resected tumors (n = 347). KRAS amplified gastric adenocarcinomas (red line; n = 23) and adenocarcinomas without KRAS amplification (blue line; n = 324). b Patients without neoadjuvant pretreatment (primary resected tumors) with KRAS amplified tumors (red line; n = 16) in comparison to patients without KRAS amplified tumors (blue line; n = 229). KRAS amplified tumors in the primary resected cohort show a statistically significant worse prognosis in comparison to non-KRAS amplified tumors (p = 0.032). c Patients with preoperative neoadjuvant treatment with KRAS amplified tumos (red line; n = 7) in comparison to patients without KRAS amplified tumors (n = 94; blue line)